. 2021 Feb 16;16(2):e0247020. doi: 10.1371/journal.pone.0247020

Table 1. Correlation between the clinicopathological parameters and CYP4B1 expression in LUAD.

Parameters	Variables	n	Mean ± SD	t	p-value
Age (years)	<65	220	8.588±2.896	2.886	0.0041
Age (years)	≥65	275	9.339±2.854	2.886	0.0041
Gender	Female	277	9.255±2.778	1.793	0.0736
Gender	Male	237	8.801±2.961	1.793	0.0736
Smoking history	1	75	9.607±3.153	1.804	0.0719
Smoking history	2/3/4/5	425	8.963±2.793	1.804	0.0719
Pathological stage	I/II	396	9.162±2.863	1.716	0.0867
Pathological stage	III/IV	110	8.634±2.817	1.716	0.0867
Pharmaceutical therapy	No	280	9.304±2.994	2.504	0.0127
Pharmaceutical therapy	Yes	188	8.653±2.586	2.504	0.0127
Radiation therapy	No	362	9.150±2.876	2.127	0.0340
Radiation therapy	Yes	107	8.308±2.762	2.127	0.0340
Mutations in KRAS/EGFR/ALK	No	134	8.938±2.842	2.274	0.0239
Mutations in KRAS/EGFR/ALK	Yes	96	9.756±2.572	2.274	0.0239
Recurrence status	No	275	9.103±2.953	0.932	0.3523
Recurrence status	Yes	162	8.838±2.826	0.932	0.3523
Living status	Living	327	9.340±2.767	3.036	0.0026
Living status	Dead	187	8.531±2.980	3.036	0.0026

LUAD, lung adenocarcinoma; SD, standard deviation.